Allogeneic haematopoietic cell transplantation (HCT) remains a potentially curative option for patients with high-risk haematological malignancies, albeit at the cost of substantial morbidity and ...
Zacks Investment Research on MSN
CareDx reports positive data for AlloHeme in AML and MDS post HCT
CareDx CDNA recently announced clinical validation data supporting AlloHeme, its next-generation, blood-based monitoring test designed to predict relapses in patients with acute myeloid leukemia (AML) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results